Intralesional immunotherapy using MMR vaccine in Molluscum contagiosum
Not Applicable
- Conditions
- Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
- Registration Number
- CTRI/2019/11/022134
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Clinically diagnosed patients with multiple ( 2 or more) lesions of Molluscum contagiosum with no history of topical or systemic therapy taken for current lesions and are willing for follow up.
Exclusion Criteria
1. Patients with a past history of allergic response to MMR or any other vaccine.
2. Patients with acute febrile illness or bacterial infections.
3. Patients with immunosuppression, HIV infection, Hepatitis B or Hepatitis C infection.
4. Patients with only anogenital lesions.
5. Pregnant or lactating women.
6. Patients having a history of asthma, allergic skin disorders or convulsions.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Resolution of the lesions based on size, number and photographic comparisonTimepoint: Every 2 weeks for first 8 weeks, then monthly till end of 6 months.
- Secondary Outcome Measures
Name Time Method To study side effects of intralesional MMR therapy. <br/ ><br>To find recurrence rate post treatment with intralesional MMR.Timepoint: Every 2 weeks for first 8 weeks, then monthly till end of 6 months.